A REVIEW ON SCREENING METHODS OF BREAST CANCER, CANCER BIOMARKERS AND PHYTOCONSTITUENTS AGAINST BREAST CANCER
DOI:
https://doi.org/10.22159/ajpcr.2017.v10i12.21039Keywords:
Cancer biomarker, Breast cancer, Phytoconstituents, Screening methodsAbstract
Â
 A cancer biomarker refers to a substance or process that is used as an indicative the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Biomarkers are utilized in three elementary ways as a diagnostic tool, prognostic tool, and predictive tool. The screening tests employed are clinical and breast exams, mammography, hereditary screening, ultrasound, and attractive reverberation imaging. Biomarkers involved in breast cancer are human epidermal growth factor-2, estrogen receptor, progesterone receptor, Cyclin D1, and Cyclin E. Specific bioactive phytoconstituents used as anticancer include curcumin, genistein, resveratrol, isothiocyanates, silymarin, diallyl sulfisoxazole, lycopene, apigenin, and gingerol. Hence, this review indicates the study of screening methods, various biomarkers in breast cancer and phytoconstituents against breast cancer.
Downloads
References
Elgadir AM, Salama M, Adam A. Anti-breast cancer from various natural sources, review. Int J Pharm Pharm Sci 2015;7(2):44-7.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, et al. Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10, Globocan. Vol. 2. Lyon, France: IARC; 2008.
Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353(17):1784-92.
Clarke M, Collins R, Darby S, Davies C, Evans V, Godwin J, et al.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Early Breast Cancer Trialists Collaborative Group. Lancet 2005;365:1687-17.
Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. 7th ed. England, UK: Wiley-Blackwell; 2009.
Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstensen B, Mouridsen HT. The Nottingham prognostic Index applied to 9,149 patients from the studies of the Danish breast cancer cooperative group (DBCG). Breast Cancer Res Treat 1994;32(3):281-90.
D’Eredita G, Giardina C, Martellotta M, Haybitlle JL, Blamey RW, et al. Prognostic factors in breast cancer: The predictive value of the Nottingham prognostic index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 2001;37:591-6.
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohisto chemical testing of oestrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-95.
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
Leake R, Barnes D, Pinder S, Ellis I, Anderson L, Anderson T, et al. Immunohistochemical detection of steroid receptors in breast cancer: A working protocol. UK Receptor Group, UK NEQAS, the Scottish breast cancer pathology group, and the receptor and biomarker study group of the EORTC. J Clin Pathol 2000;53(8):634-5.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Statistics subcommittee of the NCI-EORTC working group on cancer diagnostics. Reporting recommendations for Tumor marker prognostic studies. J Clin Oncol 2005;23(36):9067-2.
Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: A framework to evaluate clinical utility of Tumor markers. J Natl Cancer Inst 1996;88(20):1456-6.
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American society of clinical oncology 2007 update of recommendations for the use of Tumor markers in breast cancer. J Clin Oncol 2007;25(33):5287-312.
Iyer PM, Kumar PS, Karthikeyan S, Namboori PK. ‘BRCA1’ Responsiveness to wards breast cancer - A population-wise pharmacogenomics analysis. Int J Pharm Pharm Sci 2016;8(9):267-70.
Yadav R, Sen R, Chauhan P. ER, PR, HER2/NEU status and relation to clinic pathological factors in breast carcinoma. Int J Pharm Pharm Sci 2015;l(2):7.
Ramalingam S, Saravanan R, Brindha P. A review on the role of phytoconstituents in breast cancer cells. Int J PharmTech Res 2014;6(2): 799-808.
Biomarker. NCI Dictionary of Cancer Terms. National Cancer Institute. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45618.
Narayan BA, Rohit M, Abdullah F, Amit V, Dwarakanath BS. Cancer biomarkers: Current perspectives. Indian J Med Res 2010;132(2):129-49.
Biomarkers in Cancer: An Introductory Guide for Advocates 2013. p. 1-81.
Verma M, Manne U. Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations. Crit Rev Oncol Hematol 2006;60(1):9-18.
Mishra A, Verma M. Cancer biomarkers: Are we ready for the prime time? Cancers (Basel) 2010;2(1):190-208.
Kösters JP, Gøtzsche PC. Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database Syst Rev 2003;CD003373.
Breast Cancer Screening: Clinical Practice Guideline September, 2013. Available from: http://www.topalbertadoctors.org/download/243/breast_cancer_guideline.pdf?_20170406230648.
Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density and breast cancer risk: Current understanding and future prospects. Breast Cancer Res 2011;13(6):223.
Masarwah A, Auvinen P, Sudah M, Rautiainen S, Sutela A, Pelkonen O, et al. Very low mammographic breast density predicts poorer outcome in patients with invasive breast cancer. Eur Radiol 2015;25(7):1875-82.
Houssami N, Kerlikowske K. The impact of breast density on breast cancer risk and breast screening. Curr Breast Cancer Rep 2012;4:161-8.
O’Connor M, Rhodes D, Hruska C. Molecular breast imaging. Expert Rev Anticancer Ther 2009;9(8):1073-80.
Moadel RM. Breast cancer imaging devices. Semin Nucl Med 2011;41(3):229-41.
O’Connor MK, Li H, Rhodes DJ, Hruska CB, Clancy CB, Vetter RJ. Comparison of radiation exposure and associated radiation-induced cancer risks from mammography and molecular imaging of the breast. Med Phys 2010;37(12):6187-98.
Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Böhm-Vélez M, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. J Am Med Assoc 2008;299(18):2151-63.
Hung JM, Sonnad SS, Schwartz JS, Langlotz CP. Accuracy of MR imaging in the work-up of suspicious breast lesions: A diagnostic meta-analysis. Acad Radiol 1999;6(7):387-97.
Nelson HD, Huffman LH, Fu R, Harris EL. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Systematic evidence review for the U.S. preventive services task force. Ann Intern Med 2005;143(5);362-79.
Genetic Testing Facilities and Cost. Available from: http://www.breastcancer.org/symptoms/testing/genetic/facility_cost.
Easton DF. How many more breast cancer predisposition genes are there? Breast Cancer Res 1999;1(1):14-7.
Campeau PM, Foulkes WD, Tischkowitz MD. Hereditary breast cancer: New genetic developments, new therapeutic avenues. Hum Genet 2008;124(1):31-42.
Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104(12):2807-16.
Harris JR, Lippman ME, Morrow M, Osborne CK. Disease of the Breast. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004. p. 620-52.
Bauer R, Brown M, Cress RD, Parise C, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer registry. Cancer 2007;109(9):1721-8.
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747-52.
Heredia NJ, Belgrader P, Wang S, Koehler R, Regan J, Cosman AM, et al. Droplet digitalâ„¢ PCR quantitation of HER2 expression in FFPE breast cancer samples. Methods 2013;59(1):S20-3.
Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2–positive breast cancer. J Natl Cancer Inst 2004;96(12):926-35.
Debeb1 YG, Berihu BA. Review on the role of estrogen receptors in breast cancer. Int J Pharm Sci Res 2015;6(8):1100-4.
Sommer S, Fuqua SA. Estrogen receptor and breast cancer. Semin Cancer Biol 2001;11(5):339-52.
Gustafsson JA. Estrogen receptor beta - A new dimension in estrogen mechanism of action. J Endocrinol 1999;163(3):379-83.
McKenna NJ, Lanz RB, O’Malley BW. Nuclear receptor coregulators: Cellular and molecular biology. Endocr Rev 1999;20:321-44.
Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M, et al. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 1998;17(7):2008-18.
Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev 1997;18(4):502-19.
Daniel AR, Hagan CR, Lange CA. Progesterone receptor action: Defining a role in breast cancer. Expert Rev Endocrinol Metab 2011;6(3):359-69.
Musgrove EA, Lee CS, Buckley MF, Sutherland RL. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci U S A 1994;91:8022-6.
Collins K, Jacks T, Pavletich NP. The cell cycle and cancer. Proc Natl Acad Sci U S A 1997;94:2776-8.
Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 1999;39:295-312.
Sherr CJ. Cancer cell cycles. Science 1996;274(5293):1672-7.
Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347(2):1566-75.
Gray-Babin J, Zalvide J, Fox MP, Knickerbocker CJ, DeCaprio JA, Keyomarsi K, et al. Cyclin E, a redundant cycling in breast cancer. Proc Natl Acad Sci 1996;93(26):15215-20.
Sherr CJ.G1 phase progression: Cycling on cue. Cell 1994;79(4);551-5.
Nasmyth K. Control of the yeast cell cycle by the Cdc28 protein kinase. Curr Opin Cell Biol 1993;5(2):166-79.
Davies G. Time Tables of Medicine. New York: Black Dog & Leventhal; 2000.
Gutheil WG, Reed G, Ray A, Dhar A. Crocetin: An agent derived from Saffron for prevention and therapy for cancer. Curr Pharm Biotechnol 2012;13(1):173-9.
Meeran SM, Ahmed A, Tollefsbol TO. Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin Epigenetics 2010;1(3-4):101-16.
Hoensch HP, Oertel R. Emerging role of bioflavonoids in gastroenterology: Especially their effects on intestinal neoplasia. World J Gastrointest Oncol 2011;3(5):71-4.
El-Alfy TS, Ezzat SM, Hegazy AK, Amer AM, Kamel GM. Isolation of biologically active constituents from Moringa peregrine (Forssk.) Fiori. (Family: Moringaceae) growing in Egypt. Pharmacogn Mag 2011;7(26):109-15.
Nicolas C, Sebastien F, Martinez MC. Anticancer properties of flavonoids: Roles in various stages of carcinogenesis. Cardiovasc Hematol Agents Med Chem 2011;9(2):62-77.
Bachmeier BE, Mohrenz IV, Mirisola V, Schleicher E, Romeo F et al. Curcumin down regulates the inflammatory cytokines CXCL1 and-2 in breast cancer cells via NFkappaB. Carcinogenesis 2008;29(4):779-89.
Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: How many ways can curry kill tumor cells selectively? Am Assoc Pharm Sci J 2009;11(3):495-510.
Hu WE, Tin OK, Limin S, Zheng-Yuan S, Francisco F, Jong-Hun L, Ah-Ng TK. Plants against cancer: A review on natural phytochemicals in preventing and treating cancers and their drug ability. Anticancer Agents Med Chem 2012;12(10):1281-305.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
